© Reuters.
In a recent transaction, Mitch C. Hill, the Chief Financial Officer of Inari Medical, Inc. (NASDAQ:NARI), has sold a total of 6,000 shares of the company’s common stock. The sales occurred on March 12, 2024, and were executed in multiple trades with prices ranging from $41.41 to $42.32, resulting in a total transaction value of approximately $251,460.
The transactions were carried out under a Rule 10b5-1 trading plan, which was adopted by Hill on November 9, 2023. This type of plan allows company insiders to establish pre-planned transactions to sell a specified number of shares at a predetermined time. Following the sale, Hill’s direct ownership in the company stands at 183,361 shares of common stock.
In addition to the sale, Hill exercised options to acquire 6,000 shares of Inari Medical’s common stock at a price of $0.457 per share, adding to his holdings. After the exercise of options, Hill’s total direct ownership in the company’s common stock increased, reflecting his ongoing investment in Inari Medical. The options were part of a grant that began vesting on April 30, 2020, with 25% vested initially and the remainder vesting in 36 equal monthly installments.
Investors often monitor insider transactions as they can provide insights into the executives’ perspectives on the company’s current valuation and future prospects. Inari Medical, Inc., headquartered in Irvine, California, specializes in surgical and medical instruments and apparatus, and continues to be a key player in the medical technology industry.
InvestingPro Insights
As Inari Medical’s CFO Mitch C. Hill’s recent stock sale garners attention, it’s worth noting that executive transactions are just one piece of the puzzle when evaluating a company’s financial health and stock performance. Shifting focus to another company in the medical sector, ELVN, we can glean insights from InvestingPro data and tips that may inform investor decisions in this industry.
ELVN’s market capitalization currently stands at $475.59 million, reflecting its size and market value within the medical technology space. Despite this, the company’s stock has experienced significant volatility, with a 1-week price total return of -20.32% and a 1-month return of -28.54%, indicating recent market pressures. This is coupled with a notable 1-year price total return of -44.98%, suggesting a longer-term downward trend in the stock’s performance.
From a financial perspective, ELVN’s P/E ratio is negative at -6.25, which, when adjusted for the last twelve months as of Q3 2023, worsens to -7.88. This indicates that the company is not currently profitable, a sentiment echoed by an InvestingPro Tip that ELVN has not been profitable over the last twelve months. Another concerning metric is the company’s EBITDA growth for the same period, which plummeted by -88.33%, signaling potential challenges in operational efficiency and profitability.
On the brighter side, ELVN holds more cash than debt on its balance sheet, and its liquid assets exceed short-term obligations, as highlighted by InvestingPro Tips. This financial stability could provide some cushion against short-term market fluctuations and is an important factor for investors to consider.
For investors seeking a deeper dive into ELVN’s financials, metrics, and additional tips, InvestingPro offers a comprehensive analysis. There are 6 additional InvestingPro Tips available, which could provide further context to the company’s financial standing and stock performance. Interested readers can take advantage of a special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
